-
MannKind Issues Management Update
Monday, January 11, 2016 - 3:44pm | 220Read More...Shares of MannKind Corporation (NASDAQ: MNKD) were trading slightly higher by 1.58 percent at $0.67 mid-Monday afternoon after the company provided an update on its senior management team. MannKind has withdrawn its offer to employ Duane M. DeSisto as its new CEO. The company cited "...
-
Oppenheimer Maintains OP Rating, $25 PT on Insulet Corporation
Tuesday, June 7, 2011 - 9:08am | 148Read More...Oppenheimer is maintaining its $25 PT on shares of Insulet Corporation (NASDAQ: PODD) while maintaining its Outperform rating on the stock. “We are updating our model and reiterating our Outperform rating following PODD's announcement that it will acquire Neighborhood Diabetes,” Oppenheimer writes...
-
Jefferies Raises PT On Insulet Corporation To $24
Tuesday, May 10, 2011 - 6:58am | 27Read More...Jefferies & Company has raised the price target on Insulet Corporation (NASDAQ: PODD) from $20 to $24 and maintains Its Buy rating.
-
Jefferies Raises PT On Insulet Corporation To $20
Wednesday, February 16, 2011 - 7:39am | 27Read More...Jefferies & Company has raised the price target on Insulet Corporation (NASDAQ: PODD) from $19 to $20 and maintains its Buy rating.
-
Insulet Initiated At Buy, Revenues Expected To Double
Friday, December 3, 2010 - 9:17am | 80Read More...Jefferies & Company has published a research report on Insulet Corporation (NASDAQ: PODD) and has initiated coverage on the company with a Buy rating. In the report, Jefferies writes "With adoption of the OmniPod still low and next generation products on tap for 2011, Insulet is poised for...
